

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)



(10) International Publication Number
WO 2024/222647 A1

(51) International Patent Classification: SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, A61K 39/29 (2006.01) A61P 31/20 (2006.01) GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number: PCT/CN2024/089195 Published: — with international search report (Art. 21(3))

(22) International Filing Date: 22 April 2024 (22.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: PCT/CN2023/090098 23 April 2023 (23.04.2023) CN

(71) Applicant (for all designated States except CN): AUSPER-BIO THERAPEUTICS INC. [US/US]; 3 East Third Ave., Suite 200, San Mateo, California 94401 (US).

(71) Applicant (for CN only): AUSPER BIOPHARMA CO., LTD. [CN/CN]; Building 5, Room 2501, 688 Binan Road, Binjiang District, Hangzhou, Zhejiang 310052 (CN).

(72) Inventors: CHENG, Guofeng; 705 Prescott Lane, Foster City, California 94404 (US). YANG, Chengyong; 730 Tender Lane, Foster City, California 94404 (US).

(74) Agent: WU, FENG & ZHANG; 3FL, Building 4, Yard 38, Linfeng Erlu Road, Greenland Central Square, Haidian District, Beijing 100089 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: OLIGONUCLEOTIDES FOR USE IN MODULATING IMMUNE RESPONSES AGAINST HEPATITIS B VIRAL INFECTION

(57) Abstract: Provided herein are vaccine compositions comprising an oligonucleotide and a Hepatitis B viral antigen, either present in the same composition, or in separate compositions, useful for prevention or treatment of Hepatitis B viral infection in a subject. The vaccine compositions can exert a sustained immunomodulatory effect and lead to the reduction of HBV antigen levels in an infected subject. Also provided herein are methods of making and use thereof.

WO 2024/222647 A1